Phase I/II Study of Venetoclax + Low-Dose Cytarabine in Untreated, Elderly Patients With AML: Outcomes at 1 Year

Slideset - After more than 1 year of follow-up, the combination of venetoclax plus low-dose cytarabine achieved a CR + CRi rate of 62% and a median OS of 11.4 months in elderly patients with AML who are unfit for chemotherapy.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research